Meeting
2018 ASCO Annual Meeting
An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.
Authors
Anne Patsouris
Institute of West Cancerology Paul Papin, Angers, France
Anne Patsouris , Olivier Tredan , Loic Campion , Anthony Goncalves , Monica Arnedos , Marie Paule Sablin , Pascal Jézéquel , Marta Jimenez , Veronica Pezzella , Ivan Bieche , Celine Callens , Andrea Loehr , Daniel Nenciu , Cecile Vicier , Fabrice Andre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Clinical Trial Registration Number
NCT02505048
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS1112)
DOI
10.1200/JCO.2018.36.15_suppl.TPS1112
Abstract #
TPS1112
Poster Bd #
187a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.
First Author: Anne Patsouris
Poster
2018 Genitourinary Cancers Symposium
TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
First Author: Wassim Abida
Poster
2018 Genitourinary Cancers Symposium
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
First Author: Charles J. Ryan
First Author: Charles J. Ryan